Table 1

Characteristics of included studies

StudyDateFollow-up periodPatientsIntervention (MMF)Intervention (CYC)Definition of remission
Tuin J et al2620194 yearsMPA or GPA, relapse2 g/dayOral CYC 2 mg/kg/dayBVAS=0 and CRP<10 mg/dL at 6 months
Jones RB et al27201918 monthsMPA or GPA, new diagnosis2 g/day (dose up to 3 g/day permitted)Intravenous pulsed CYC 15 mg/kg every 2–3 weeksBVAS=0 at 2 occasions apart within 6 months
Han F et al2820116 monthsMPA1.0 g/day (1.5 g/day if BW>70 kg)Intravenous pulse CYC, 1.0 g/body monthlyBVAS=0 with PSL<7.5 mg/day at 6 months
Hu W et al2920086 monthsMPA or GPA, new diagnosis2.0 g/day (1.5 g/day if BW<50 kg)Intravenous pulse CYC, 0.75–1.0 g/m2 body surface area monthlyBVAS=0 at 6 months
  • BVAS, Birmingham Vasculitis Activity Score; CYC, cyclophosphamide; GPA, granulomatosis with polyangiitis; MMF, mycophenolate mofetil; MPA, microscopic polyangiitis; PSL, prednisolone.